Weekly Recap | CHINARES PHARMA -5.79%, consensus target above spot

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

CHINARES PHARMA (3320.HK) fell 5.79% this week to close at HK$4.395, compared with a 3.32% drop for the Hang Seng Index, trailing the benchmark by about 2.47 percentage points. The stock traded lower across all four sessions: it opened Monday at HK$4.665, slipped to HK$4.540 on Tuesday and finished the week at its low of HK$4.395 on Thursday, a steady downward drift. Weekly amplitude was 6.22%, while average daily volume of 6.0m shares sat 21.4% below its 60-day median, leaving a quiet tape with no company-specific catalyst.\n\n## Analyst Ratings\n\nAmong 11 brokers covering the stock, 6 rate it buy, 4 rate it overweight and 1 hold, with no underweight or sell calls; the consensus rating is buy. The consensus target price of HK$6.489 sits about 47.6% above the spot price, with the highest target at HK$7.520 and the lowest at HK$5.640, suggesting moderate dispersion. Within the 29-name pharmaceutical sector coverage, it ranks fifth by number of ratings.\n\n## The Week Ahead\n\nHong Kong releases its unemployment rate on 17 November (previous 3.9%) and the composite CPI on 20 November (previous 1.9%). On the corporate side, CHINARES PHARMA reports fiscal Q3 results after market close on 24 November, putting revenue and profit trends in focus. With the stock now below its 20-day moving average, next week’s volume recovery is another thing to watch.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.